
With an investment of DKK 17bn (USD 2.6bn), Novo Nordisk seeks to strengthen all of the links in its global value chain, from drug production to packaging, it announces in a press release on Monday.
The sum will be spent on three new manufacturing facilities plus an expansion of its existing facility in Kalundborg, Denmark, with the goal of establishing additional capacity for the production of active pharmaceutical ingredients (APIs).
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app